Citations

Clear

4847 citation(s) found for "Yu, Eric".

Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use
Zakroysky, Pearl, Xiang, Qun, Goldberg, Anne C. , Robinson, Jennifer G. , Roger, Véronique L. , Wilson, Peter W.F. , Elassal, Joseph, Lee, L. Veronica, Wang, Tracy Y., Nanna, Michael G. , Návar, Ann Marie , Virani, Salim S. , Peterson, Eric D.

Mayo Clinic

JAMA Cardiology | June 13, 2018 | Volume: 3 | Issue: 8 | Pages: 739

10.1001/jamacardio.2018.1511 | PMID 29898219 Get It

Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
O’Brien, Emily C. , Holmes, DaJuanicia N. , Thomas, Laine , Kowey, Peter R. , Ansell, Jack , Piccini, Jonathan P. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Gersh, Bernard J. , Peterson, Eric D. , Hylek, Elaine M.

Mayo Clinic

Journal of the American Heart Association | June 9, 2018 | Volume: 7 | Issue: 12 | Pages: No page available

10.1161/jaha.117.006391 | PMID 29886422 Get It

Background Oral anticoagulation ( OAC ) reduces stroke risk in atrial fibrillation, but bleeding is a frequent side effect. The decision to discontinue or modify medication regimens in response to a bleeding event may differ according to bleeding site and severity. Methods and Results We used data from a large, national outpatient registry, ORBIT ‐ AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; 2010–2011), to evaluate event characteristics and OAC management following the first bleeding event occurring during follow‐up. Bleeding events were classified into 3 categories: (1) International Society of Thrombosis and Hemostasis major bleeding, (2) clinically relevant nonmajor bleeding requiring medical attention, and (3) nuisance bleeding not requiring medical attention (eg, bruising, hemorrhoidal bleeding). Of 9743 patients enrolled in ORBIT ‐ AF with follow‐up data, 510 (3.23/100 subject‐years) experienced a major bleed, 615 (3.90/100 subject‐years), experienced a clinically relevant nonmajor bleed, and 1558 (9.87/100 subject‐years) experienced a nuisance bleed, among first bleeds over 2 years. Nearly one third of patients (31.6%) discontinued OAC therapy following a major bleeding event, 12.7% following a clinically relevant nonmajor bleed, and 4.5% following a nuisance bleed. Compared with those who experienced a clinically relevant nonmajor or nuisance bleed, patients who experienced a major bleed were more likely to be black and female and to have a history of heart failure and stroke. Those who discontinued were more likely to have central nervous system or gastrointestinal bleeding than those who persisted on OAC therapy. Conclusions Overall, 1 in 3 patients who experienced a major bleed was no longer anticoagulated after the event. Those who discontinued OAC were more likely to have central nervous system or gastrointestinal bleeding than those who persisted on OAC .
Complications following pediatric cranioplasty after decompressive craniectomy: a multicenter retrospective study
Rocque, Brandon G. , Agee, Bonita S. , Thompson, Eric M. , Piedra, Mark, Baird, Lissa , Greene, Stephanie , Deibert, Christopher P., Hankinson, Todd C. , Lew, Sean M. , Iskandar, Bermans J. , Bragg, Taryn, Frim, David M. , Gupta, Nalin , Auguste, Kurtis I. , Nikas, Dimitrios C., Vassilyadi, Michael, Muh, Carrie R. , Wetjen, Nicholas M. , Lam, Sandi , Selden, Nathan R. W. , Grant, Gerald A. , Muh, Carrie R

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 8, 2018 | Volume: 22 | Issue: 3 | Pages: 225-232

10.3171/2018.3.peds17234 | PMID 29882736 Get It

OBJECTIVEIn children, the repair of skull defects arising from decompressive craniectomy presents a unique set of challenges. Single-center studies have identified different risk factors for the common complications of cranioplasty resorption and infection. The goal of the present study was to determine the risk factors for bone resorption and infection after pediatric cranioplasty.METHODSThe authors conducted a multicenter retrospective case study that included all patients who underwent cranioplasty to correct a skull defect arising from a decompressive craniectomy at 13 centers between 2000 and 2011 and were less than 19 years old at the time of cranioplasty. Prior systematic review of the literature along with expert opinion guided the selection of variables to be collected. These included: indication for craniectomy; history of abusive head trauma; method of bone storage; method of bone fixation; use of drains; size of bone graft; presence of other implants, including ventriculoperitoneal (VP) shunt; presence of fluid collections; age at craniectomy; and time between craniectomy and cranioplasty.RESULTSA total of 359 patients met the inclusion criteria. The patients’ mean age was 8.4 years, and 51.5% were female. Thirty-eight cases (10.5%) were complicated by infection. In multivariate analysis, presence of a cranial implant (primarily VP shunt) (OR 2.41, 95% CI 1.17–4.98), presence of gastrostomy (OR 2.44, 95% CI 1.03–5.79), and ventilator dependence (OR 8.45, 95% CI 1.10–65.08) were significant risk factors for cranioplasty infection. No other variable was associated with infection.Of the 240 patients who underwent a cranioplasty with bone graft, 21.7% showed bone resorption significant enough to warrant repeat surgical intervention. The most important predictor of cranioplasty bone resorption was age at the time of cranioplasty. For every month of increased age the risk of bone flap resorption decreased by 1% (OR 0.99, 95% CI 0.98–0.99, p < 0.001). Other risk factors for resorption in multivariate models were the use of external ventricular drains and lumbar shunts.CONCLUSIONSThis is the largest study of pediatric cranioplasty outcomes performed to date. Analysis included variables found to be significant in previous retrospective reports. Presence of a cranial implant such as VP shunt is the most significant risk factor for cranioplasty infection, whereas younger age at cranioplasty is the dominant risk factor for bone resorption.
De Novo DNM1L Variant in a Teenager With Progressive Paroxysmal Dystonia and Lethal Super-refractory Myoclonic Status Epilepticus
Ryan, Conor S. , Fine, Anthony L. , Cohen, Alexander L. , Schiltz, Brenda , Renaud, Deborah L. , Patterson, Marc C. , Boczek, Nicole J. , Babovic‐Vuksanovic, Dusica , Payne, Eric T. , Schiltz, Brenda M, Wirrell, Elaine C., Babovic-Vuksanovic, Dusica, Fine, Anthony , Cohen, Alexander , Wirrell, Elaine , Liu, Raymond, Chan, David C. M. , Patterson, Marc

Mayo Clinic

Journal of Child Neurology | June 7, 2018 | Volume: 33 | Issue: 10 | Pages: 651-658

10.1177/0883073818778203 | PMID 29877124 Get It

Background: The dynamin 1-like gene ( DNM1L) encodes a GTPase that mediates mitochondrial and peroxisomal fission and fusion. We report a new clinical presentation associated with a DNM1L pathogenic variant and review the literature. Results: A 13-year-old boy with mild developmental delays and paroxysmal dystonia presented acutely with multifocal myoclonic super-refractory status epilepticus. Despite sustained and aggressive treatment, seizures persisted and care was ultimately withdrawn in the context of extensive global cortical atrophy. Rapid trio-whole exome sequencing revealed a de novo heterozygous c.1207C>T (p.R403C) pathogenic variant in DNM1L. Immunofluorescence staining of fibroblast mitochondria revealed abnormally elongated and tubular morphology. Conclusions: This case highlights the diagnostic importance of rapid whole exome sequencing within a critical care setting and reveals the expanding phenotypic spectrum associated with DNM1L variants. This now includes progressive paroxysmal dystonia and adolescent-onset super-refractory myoclonic status epilepticus contributing to strikingly rapid and progressive cortical atrophy and death.
Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 90-100

10.1089/humc.2017.142 | PMID 29869540 Get It

Self-Complementary Adeno-Associated Virus–Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 101-112

10.1089/humc.2017.143 | PMID 29869535 Get It

Caloric Intake, Aging, and Mild Cognitive Impairment: A Population-Based Study
Geda, Yonas E. , Ragossnig, Marion, Roberts, Lewis A., Roberts, Rosebud O., Christianson, Teresa J., Levine, James A. , Sochor, Ondřej , Tangalos, Eric G., Petersen, Ronald C. , Geda, Yonas E , Pankratz, V. Shane , Mielke, Michelle M. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 34 | Issue: 2 | Pages: 501-507

10.3233/jad-121270 | PMID 23234878 Get It

Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention
Caselli, Richard J. , Reiman, Eric M.

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 33 | Issue: s1 | Pages: S405-S416

10.3233/jad-2012-129026 | PMID 22695623 Get It

Proposal for Modification of Cahan's Criteria Utilizing Molecular Genetic Analyses for Cases without Baseline Histopathology: A Unique Method Applicable to Primary Radiosurgery
Rusheen, Aaron E. , Smadbeck, James B. , Schimmenti, Lisa A. , Klee, Eric W. , Link, Michael J. , Vasmatzis, George , Carlson, Matthew L. , Schimmenti, Lisa A

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 31, 2018 | Volume: 80 | Issue: 01 | Pages: 010-017

10.1055/s-0038-1655759 | PMID 30733895 Get It

Background Cahan's criteria have been utilized since 1948 to establish causality between prior radiation treatment and the development of secondary malignancy. One major criterion specifies that histological and radiographic evidence collected before and after radiation treatment must confirm separate tumor types; however, pretreatment biopsy is rarely obtained prior to radiosurgery for vestibular schwannoma and many other skull base and cranial lesions. Therefore, in these cases Cahan's criteria cannot be validly applied. Objective This article proposes an update to Cahan's criteria using modern molecular genetic analysis for cases lacking baseline histopathology. Methods Mate-pair sequencing and whole exome sequencing of a cerebellopontine angle undifferentiated high-grade pleomorphic sarcoma (UHGPS) that developed after stereotactic radiosurgery of a presumed benign vestibular schwannoma. Results Mate-pair sequencing and whole exome sequencing of the sarcoma revealed complex chromosomal aberrations. Notably, the tumor contained a deletion in the NF2 gene at 22q12 and an in-frame deletion on exon 5 of the remaining copy of NF2. Biallelic events impacting NF2 are atypical for UHGPS but are characteristic for vestibular schwannoma. These findings help support the conclusion that the UHGPS arose from a benign vestibular schwannoma all along. Conclusions Next-generation sequencing can be successfully applied to a radiation-induced sarcoma when both the original and malignant tumors harbor separate signature genetic markers. As our understanding of the genetic profile of various tumors expand, we believe that next-generation sequencing and other genomic tools will play an increasingly important role in establishing causality between radiation and the development of secondary malignancy.